Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02344290 · ClinicalTrials.gov registry record · Phase 3
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
A Phase 3 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 3
- Development phase
- 7,769
- Enrollment target
NCT02344290: Completed Phase 3 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT02344290 is a Phase 3 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 7,769 participants, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (908% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02344290, a Phase 3 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 7,769 participants
- Enrollment target
Study Summary
People with HIV are at risk for cardiovascular disease (CVD). This study evaluated the use of pitavastatin to reduce the risk of CVD in adults with HIV on antiretroviral therapy (ART). The REPRIEVE trial consisted of two parallel identical protocols: * REPRIEVE (A5332) was funded by the NHLBI, with additional infrastructure support provided by the NIAID, and was conducted in U.S and select international sites (approximately 120 sites in 11 countries). * REPRIEVE (EU5332) was co-sponsored by NEAT ID and MGH, and was conducted at 13 sites in Spain.
Primary Outcome
MACE is a composite of cardiovascular (CV) death, myocardial infarction, hospitalization for unstable angina, stroke, transient ischemic attack (TIA), peripheral arterial ischemia, coronary, carotid or peripheral arterial revascularization, or death from an undetermined cause. The incidence rates were estimated based on time to the first event using Poisson distribution, with follow-up time censored at last contact. The treatment effect was estimated via cause-specific relative hazard (i.e. haza
Interventions
- DRUG Placebo
- DRUG Pitavastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,769 participants |
| Start Date | 2015-03-26 |
| Est. Completion | 2023-08-21 |
| Phase | Phase 3 |
What the finished NCT02344290 record still lists
NCT02344290 is an interventional study that assigns participants to a tested intervention. Its 7,769 participants enrollment target places it among the larger protocols in the corpus, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (908% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02344290 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02344290 about?
NCT02344290 is a clinical study titled "Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults". People with HIV are at risk for cardiovascular disease (CVD). This study evaluated the use of pitavastatin to reduce the risk of CVD in adults with HIV on antiretroviral therapy (ART). The REPRIEVE trial consisted of two parallel identical protocols: * REPRIEVE (A5332) was funded by the NHLBI, wit...
What is the current status of trial NCT02344290?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 7,769 participants. The study started on 2015-03-26. Estimated completion is 2023-08-21.
What interventions are being tested in trial NCT02344290?
The interventions under investigation include: Placebo (DRUG), Pitavastatin (DRUG).
Who is sponsoring clinical trial NCT02344290?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02344290's enrollment target sits among peer trials
7,769 33rd of 2000 higher than 1,968 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06560398 · 7,649 participants · NA
Working Through Outreach, Navigation and Digital Enabled Referral and Recruitment Strategies (ACT WONDER²S)
- NCT03848312 · 7,600 participants · Phase 3
Preventing Alzheimer's With Cognitive Training
- NCT00539162 · 8,000 participants · NA
Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women
- NCT00898638 · 8,000 participants
Tissue Sample Collection From Patients With Head and Neck Cancer and From Healthy Participants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI